Blood lipids in 75,048 type 2 diabetic patients: A population-based survey from the Swedish National diabetes register

European Journal of Preventive Cardiology

Volumn 18, Issue 1, 2011, Pages 97-105

  Eriksson, Mats ^a   Zethelius, Björn ^b   Eeg Olofsson, Katarina ^c   Nilsson, Peter M ^d   Gudbjörnsdottir, Soffia ^c   Cederholm, Jan ^b   Eliasson, Björn ^c  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

Blood lipids; cholesterol; epidemiology; high density lipoprotein cholesterol; low density lipoprotein cholesterol; triglycerides; type 2 diabetes

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; STROKE; SWEDEN;

AGE FACTORS; AGED; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; LIPIDS; MALE; MIDDLE AGED; POPULATION SURVEILLANCE; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; SEX FACTORS; SWEDEN; TIME FACTORS; TRIGLYCERIDES;

EID: 79955707469     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1097/HJR.0b013e32833ba61e     Document Type: Article

References (35)

1. Deckert T, Poulsen JE, Larsen M. Prognosis of diabetics with diabetes onset before the age of thirty-one. I. Survival, causes of death, and complications. Diabetologia 1978; 14: 363–370.
2. Morrish NJ, Stevens LK, Head J, Fuller JH, Jarrett RJ, Keen H. A prospective study of mortality among middle-aged diabetic patients (the London Cohort of the WHO Multinational Study of Vascular Disease in Diabetics) II: associated risk factors. Diabetologia 1990; 33: 542–548.
3. American Diabetes Association. Standards of medical care in diabetes-2008. Diabetes care 2008; 31(suppl 1): S12–S54.
4. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 14(Suppl 2): S1–S113.
5. Krauss RM. Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care 2004; 27: 1496–1504.
6. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl Med 1998; 339: 229–234.
7. Howard BV, Robbins DC, Sievers ML, Lee ET, Rhoades D, Devereux RB, et al. LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study. Arterioscler Thrombos, Vasc Biol 2000; 20: 830–835.
8. Multiple Risk Factor Intervention Trial Research Group. Multiple risk factor intervention trial. Risk factor changes and mortality results. JAMA 1982; 248: 1465–1477.
9. Kannel WB. Lipids, diabetes, and coronary heart disease: insights from the Framingham Study. Am Heart J 1985; 110: 1100–1107.
10. Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Nilsson P, Gudbjörnsdóttir S. Risk prediction of cardiovascular disease in type 2 diabetes: A risk equation from the Swedish National Diabetes Register (NDR). Diabetes Care 2008; 31: 2038–2043.
11. Eeg-Olofsson K, Cederholm J, Nilsson P, Nunez L, Gudbjörnsdottir S, Eliasson B. Overweight, obesity and cardiovascular complications and death in type 2 diabetes. An observational study in 10 896 patients from the National Diabetes Register (NDR) in Sweden. Diabetologia 2009; 52: 65–73.
12. Nilsson PM, Cederholm J, Eeg-Olofsson K, Eliasson B, Zethelius B, Fagard R, et al. Smoking as an independent risk factor for myocardial infarction or stroke in type 2 diabetes: a report from the Swedish National Diabetes Register (NDR). Eur J Cardiovasc Prev Rehabil 2009; 16: 506–512.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesteroi in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.
14. The National Board of Health and Welfare. Stockholm, Sweden2008 [cited 2009]; Available from: http://www.socialstyrelsen.se/english.
15. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, age, cardiovascular risk factors, and coronary heart disease: a prospective follow-up study of 14 786 middle-aged men and women in Finland. Circulation 1999; 99: 1165–1172.
16. Juutilainen A, Kortelainen S, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Gender difference in the impact of type 2 diabetes on coronary heart disease risk. Diabetes Care 2004; 27: 2898–2904.
17. Natarajan S, Liao Y, Cao G, Lipsitz SR, McGee DL. Sex differences in risk for coronary heart disease mortality associated with diabetes and established coronary heart disease. Arch Intern Med 2003; 163: 1735–1740.
18. Stamler J, Stamler R, Neaton JD, Wentworth D, Daviglus ML, Garside D, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA 1999; 282: 2012–2018.
19. Walldius G, Jungner I, Holme I, Aastveit AH, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-I, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026–2033.
20. Benn M, Nordestgaard BG, Jensen GB, Tybjaerg-Hansen A. Improving prediction of ischemic cardiovascular disease in the general population using Apolipoprotein B. The Copenhagen City Heart Study. Arterioscler, Thromb, Vasc Biol 2007; 27: 661–670.
21. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, et al. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005; 294: 1773–1781.
22. Zhang L, Qiao Q, Tuomilehto J, Hammar N, Alberti KGMM, Eliasson M, et al. Blood lipid levels in relation to glucose status in European men and women without a prior history of diabetes: The DECODE Study. Diabetes Res Clin Pract 2008; 82: 364–377.
23. Eliasson M, Janlert U, Jansson JH, Stegmayr B. Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J Intern Med 2006; 260: 551–559.
24. Kanaya AM, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med 2002; 162: 1737–1745.
25. Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R, et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Eur Heart J 2007; 28: 2375–2414.
26. Ryden L, Standl E, Bartnik M, Van den Berghe G, Betteridge J, de Boer MJ, et al. Guidelines on diabetes, pre-diabetes, and cardiovascular diseases: executive summary. The Task Force on Diabetes and Cardiovascular Diseases of the European Society of Cardiology (ESC) and of the European Association for the Study of Diabetes (EASD). Eur Heart J 2007; 28: 88–136.
27. Gudbjornsdottir S, Eeg-Olofsson K, Cederholm J, Zethelius B, Eliasson B, Nilsson PM. Risk factor control in patients with Type 2 diabetes and coronary heart disease: findings from the Swedish National Diabetes Register (NDR). Diabet Med 2009; 26: 53–60.
28. Hermans MP, Van Mieghem W, Vandenhoven G, Vissers E. Centralized Pan-European survey on the undertreatment of hypercholesterolaemia (CEPHEUS). Acta Cardiol 2009; 64: 177–185.
29. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–591.
30. Berthezene F. Non-insulin dependent diabetes and reverse cholesterol transport. Atherosclerosis 1996; 124(Suppl): S39–S42.
31. Kontush A, Chapman MJ. Antiatherogenic small, dense HDL-guardian angel of the arterial wall? Nat Clin Pract Cardiovasc Med 2006; 3: 144–153.
32. Hoang A, Murphy AJ, Coughlan MT, Thomas MC, Forbes JM, O'Brien R, et al. Advanced glycation of apolipoprotein A-I impairs its anti-atherogenic properties. Diabetologia 2007; 50: 1770–1779.
33. Navab M, Anantharamaiah GM, Reddy ST, Lenten BJV, Fogelman AM. HDL as a biomarker, potential therapeutic target, and therapy. Diabetes 2009; 58: 2711–2717.
34. Taskinen M-R. Diabetic dyslipidaemia: from basic research to clinical practice. Diabetologia 2003; 46: 733–749.
35. Sniderman AD, Blank D, Zakarian R, Bergeron J, Frohlich J. Triglycerides and small dense LDL: the twin Achilles heels of the Friedewald formula. Clin Biochem 2003; 36: 499–504.